Sustained decrease in blood pressure following missed doses of aliskiren or telmisartan: The ASSERTIVE double-blind, randomized study

Journal of Hypertension

Volumn 30, Issue 5, 2012, Pages 1029-1040

  Düsing, Rainer ^a   Brunel, Patrick ^b   Baek, Inyoung ^b   Baschiera, Fabio ^b  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

aliskiren; ambulatory blood pressure; angiotensin receptor blocker; antihypertensive therapy; blood pressure variability; direct renin inhibitor; drug holiday; telmisartan

Indexed keywords

ALISKIREN; PLACEBO; TELMISARTAN;

ACUTE HEART INFARCTION; ACUTE PANCREATITIS; ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; BRAIN ISCHEMIA; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIVERTICULITIS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG FATALITY; DRUG WITHDRAWAL; ESSENTIAL HYPERTENSION; FEMALE; FEMUR FRACTURE; HEADACHE; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SYSTOLIC BLOOD PRESSURE; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 84859892353     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328351c263     Document Type: Article

References (30)

1. Breekveldt-Postma NS, Penning-van Beest FJ, Siiskonen SJ, Falvey H, Vincze G, Klungel OH, et al. The effect of discontinuation of antihypertensives on the risk of acute myocardial infarction and stroke. Curr Med Res Opin 2008; 24:121-127. (Pubitemid 351160245)
2. Breekveldt-Postma NS, Penning-van Beest FJ, Siiskonen SJ, Koerselman J, Klungel OH, Falvey H, et al. Effect of persistent use of antihypertensives on blood pressure goal attainment. Curr Med Res Opin 2008; 24:1025-1031. (Pubitemid 351579159)
3. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010; 303:2043-2050.
4. Kettani FZ, Dragomir A, Cote R, Roy L, Berard A, Blais L, et al. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke 2009; 40:213-220.
5. Dusing R. Overcoming barriers to effective blood pressure control in patients with hypertension. Curr Med Res Opin 2006; 22:1545-1553. (Pubitemid 44297433)
6. Hermida RC, Ayala DE, Khder Y, Calvo C. Ambulatory blood pressurelowering effects of valsartan and enalapril after a missed dose in previously untreated patients with hypertension: a prospective, randomized, open-label, blinded end-point trial. Clin Ther 2008; 30:108-120. (Pubitemid 351834726)
7. Hernandez RH, Armas-Hernandez MJ, Chourio JA, Armas-Padilla MC, Lopez L, Alvarez M, et al. Comparative effects of amlodipine and nifedipine GITS during treatment and after missing two doses. Blood Press Monit 2001; 6:47-57. (Pubitemid 32269931)
8. Hernandez-Hernandez R, Armas de Hernandez MJ, Armas-Padilla MC, Carvajal AR, Guerrero-Pajuelo J. The effects of missing a dose of enalapril versus amlodipine on ambulatory blood pressure. Blood Press Monit 1996; 1:121-126. (Pubitemid 126440487)
9. Johnson MD, Fahri ER, Troen BR, Barger AC. Plasma epinephrine and control of plasma renin activity: possible extrarenal mechanisms. Am J Physiol 1979; 236:H854-H859. (Pubitemid 9220436)
10. Calhoun DA, Lacourciere Y, Chiang YT, Glazer RD. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension 2009; 54:32-39.
11. Leenen FH, Fourney A, Notman G, Tanner J. Persistence of antihypertensive effect after 'missed doses' of calcium antagonist with long (amlodipine) vs short (diltiazem) elimination half-life. Br J Clin Pharmacol 1996; 41:83-88. (Pubitemid 26059122)
12. Osterberg LG, Urquhart J, Blaschke TF. Understanding forgiveness: minding and mining the gaps between pharmacokinetics and therapeutics. Clin Pharmacol Ther 2010; 88:457-459.
13. Palatini P, Jung W, Shlyakhto E, Botha J, Bush C, Keefe DL. Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study. J Hum Hypertens 2010; 24:93-103.
14. Ribeiro AB, Mion D Jr, Marin MJ, Majul C, Botero R, Lopez R, et al. Antihypertensive efficacy of amlodipine and losartan after two 'missed' doses in patients with mild to moderate essential hypertension. J Int Med Res 2007; 35:762-772. (Pubitemid 350238409)
15. Vaur L, Dutrey-Dupagne C, Boussac J, Genes N, Bouvier d'Yvoire M, Elkik F, et al. Differential effects of a missed dose of trandolapril and enalapril on blood pressure control in hypertensive patients. J Cardiovasc Pharmacol 1995; 26:127-131.
16. Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 2008; 336:1114-1117. (Pubitemid 351731741)
17. Kario K, Lowy A, Munk VC, Annemans L. 24-hour blood pressure control: a predictor for clinical outcomes. Curr Hypertens Rev 2009; 5:102-122.
18. Waeber B, Burnier M, Brunner HR. Compliance with antihypertensive therapy. Clin Exp Hypertens 1999; 21:973-985. (Pubitemid 29325494)
19. Black HR, Kribben A, Aguirre Palacios F, Bijarnia M, Laflamme AK, Baschiera F. Aliskiren alone or in combination with hydrochlorothiazide in patients with the lower ranges of stage 2 hypertension: the ACQUIRE randomized double-blind study. J Clin Hypertens (Greenwich) 2010; 12:917-926.
20. Oh BH, Mitchell J, Herron JR, Chung J, Khan M, Keefe DL. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-h blood pressure control in patients with hypertension. J Am Coll Cardiol 2007; 49:1157-1163. (Pubitemid 46400330)
21. Andersen K, Weinberger MH, Egan B, Constance CM, Ali MA, Jin J, et al. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens 2008; 26:589-599.
22. Boschmann M, Nussberger J, Engeli S, Danser AH, Yeh CM, Prescott MF, et al. Aliskiren penetrates adipose and skeletal muscle tissue and reduces renin-angiotensin system activity in obese hypertensive patients. J Hypertens 2012; 30:561-566.
23. Azizi M, Webb R, Nussberger J, Hollenberg NK. Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens 2006; 24:243-256. (Pubitemid 43348229)
24. McInnes G. 24-h powerful blood pressure-lowering: is there a clinical need? J Am Soc Hypertens 2008; 2:S16-S22. (Pubitemid 351954455)
25. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187. (Pubitemid 46924065)
26. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997
27. Os I, Gudmundsdottir H, Kjeldsen SE, Oparil S. Treatment of isolated systolic hypertension in diabetes mellitus type 2. Diabetes Obes Metab 2006; 8:381-387. (Pubitemid 44349229)
28. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004; 364:1684-1689. (Pubitemid 39458144)
29. Sever P. The Anglo-Scandinavian Cardiac Outcomes Trial Blood Pressure Lowering Arm (ASCOT-BPLA): Blood Pressure Variability and Cardiovascular Outcomes. J Am Coll Cardiol 2010; 55:11-318.
30. Kim BH, Kim JR, Kim MG, Kim KP, Lee BY, Jang IJ, et al. Pharmacodynamic (hemodynamic) and pharmacokinetic comparisons of S-amlodipine gentisate and racemate amlodipine besylate in healthy Korean male volunteers: two double-blind, randomized, two-period, two-treatment, two-sequence, double-dummy, single-dose crossover studies. Clin Ther 2010; 32:193-205.